Mast cell activation syndrome (MCAS) affects more than 15% of the U.S. population but evades most practitioners’ radar. Just five years ago, it wasn’t even on my radar, despite already having 20 years of experience as a clinician at that time. The more I dug (similar to leaky gut and post-COVID syndrome), the more I found my patients were suffering from this disorder.
Daniel Ruscigno
Daniel Ruscigno is the co-founder of ClinicSense. ClinicSense offers clinic management software that helps with scheduling, intake forms, SOAP notes, billing, and more. Visit www.ClinicSense.com.